| Richard Anthony Beller, MD | |
|
700 M St Ne, Auburn, WA 98002-4586 | |
| (206) 212-2100 | |
| (206) 212-2194 |
| Full Name | Richard Anthony Beller |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 46 Years |
| Location | 700 M St Ne, Auburn, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396741005 | NPI | - | NPPES |
| G40056 | Medicaid | CA | |
| 2112080 | Medicaid | WA | |
| G8990641 | Other | WA | MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | G40056 (California) | Secondary |
| 207W00000X | Ophthalmology | MD60818145 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eye Care Center Of Napa Valley A Medical Corporation | 5496723793 | 8 |
| Evergreen Eye Center Pllc | 3173410057 | 12 |
News Archive
Conquering the last frontier for monitoring vital signs, Brain Tunnelgenix Technologies Corp. is introducing the Abreu btt™ 700 System for continuous temperature monitoring at the Annual Meeting of the American Society of Anesthesiologists (ASA) today. The Abreu btt 700 System sensor is approved by the U.S. Food and Drug Administration for placement on the skin and to be used during surgical procedures, recovery room, intensive care and general patient monitoring.
The National Hemophilia Foundation has awarded CSL Behring its 2015 Corporate Leadership Award as recognition for the company's longstanding and unwavering commitment to advancing science and improving the care of the bleeding disorders community. The award was accepted by Paul Perreault, CEO and Managing Director, CSL Limited, during the NHF Annual Spring Soiree in New York City on May 21.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
The number of children and young adults with autoimmune diseases receiving the HPV vaccination is profoundly low despite studies showing the vaccine to be safe and effective, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. Given the increased incidence of HPV in people with autoimmune diseases, this research suggests that increased public health efforts are needed.
› Verified 1 days ago
| Entity Name | Eye Care Center Of Napa Valley A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790781409 PECOS PAC ID: 5496723793 Enrollment ID: O20040923001129 |
News Archive
Conquering the last frontier for monitoring vital signs, Brain Tunnelgenix Technologies Corp. is introducing the Abreu btt™ 700 System for continuous temperature monitoring at the Annual Meeting of the American Society of Anesthesiologists (ASA) today. The Abreu btt 700 System sensor is approved by the U.S. Food and Drug Administration for placement on the skin and to be used during surgical procedures, recovery room, intensive care and general patient monitoring.
The National Hemophilia Foundation has awarded CSL Behring its 2015 Corporate Leadership Award as recognition for the company's longstanding and unwavering commitment to advancing science and improving the care of the bleeding disorders community. The award was accepted by Paul Perreault, CEO and Managing Director, CSL Limited, during the NHF Annual Spring Soiree in New York City on May 21.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
The number of children and young adults with autoimmune diseases receiving the HPV vaccination is profoundly low despite studies showing the vaccine to be safe and effective, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. Given the increased incidence of HPV in people with autoimmune diseases, this research suggests that increased public health efforts are needed.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Anthony Beller, MD 34719 6th Ave S, Federal Way, WA 98003-8714 Ph: (206) 212-2100 | Richard Anthony Beller, MD 700 M St Ne, Auburn, WA 98002-4586 Ph: (206) 212-2100 |
News Archive
Conquering the last frontier for monitoring vital signs, Brain Tunnelgenix Technologies Corp. is introducing the Abreu btt™ 700 System for continuous temperature monitoring at the Annual Meeting of the American Society of Anesthesiologists (ASA) today. The Abreu btt 700 System sensor is approved by the U.S. Food and Drug Administration for placement on the skin and to be used during surgical procedures, recovery room, intensive care and general patient monitoring.
The National Hemophilia Foundation has awarded CSL Behring its 2015 Corporate Leadership Award as recognition for the company's longstanding and unwavering commitment to advancing science and improving the care of the bleeding disorders community. The award was accepted by Paul Perreault, CEO and Managing Director, CSL Limited, during the NHF Annual Spring Soiree in New York City on May 21.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
The number of children and young adults with autoimmune diseases receiving the HPV vaccination is profoundly low despite studies showing the vaccine to be safe and effective, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. Given the increased incidence of HPV in people with autoimmune diseases, this research suggests that increased public health efforts are needed.
› Verified 1 days ago
Dr. Rahul Mandiga, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 125 3rd St Ne Ste 200, Auburn, WA 98002 Phone: 253-275-1000 Fax: 253-275-9000 | |
Dr. Joshua Frenkel, MD, MPH Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 700 M St Ne, Auburn, WA 98002 Phone: 206-222-1709 Fax: 855-929-1515 | |
Benjamin Reiss, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 125 3rd St Ne Ste 200, Auburn, WA 98002 Phone: 253-275-1000 Fax: 253-275-9000 |